Cover Image
市場調查報告書

BioNTech AG:產品平台分析

BioNTech AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 342296
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
BioNTech AG:產品平台分析 BioNTech AG - Product Pipeline Review - 2015
出版日期: 2015年09月16日 內容資訊: 英文 25 Pages
簡介

BioNTech AG是開發創新治療藥和生物標記診斷方法的生物製藥公司,其產品網羅了傳訊RNA藥,細胞療法,遺傳基因療法,重組疫苗,免疫刺激劑的範圍。該公司同時也支援黑色素瘤,乳癌,神經膠母細胞瘤,卵巢癌,各種感染疾病,過敏,自體免疫不全等治療領域。

本報告提供BioNTech AG 的治療藥開發平台的現狀及各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,被休止的計劃相關資訊等。

BioNTech AG的基本資料

  • BioNTech AG概要
  • 主要資訊
  • 企業資料

BioNTech AG:R&D概要

  • 主要的治療範圍

BioNTech AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

BioNTech AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅰ期的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

BioNTech AG:藥物簡介

BioNTech AG:開發平台分析

  • 各給藥途徑
  • 各分子類型

BioNTech AG:暫停中的計劃

BioNTech AG:總公司和子公司的所在地

  • 總公司
  • 其他據點及子公司

附錄

圖表

目錄
Product Code: GMDHC07579CDB

Summary

Global Markets Direct's, 'BioNTech AG - Product Pipeline Review - 2015', provides an overview of the BioNTech AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioNTech AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of BioNTech AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of BioNTech AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the BioNTech AG's pipeline products

Reasons to buy

  • Evaluate BioNTech AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of BioNTech AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the BioNTech AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of BioNTech AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioNTech AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of BioNTech AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BioNTech AG Snapshot
    • BioNTech AG Overview
    • Key Information
    • Key Facts
  • BioNTech AG - Research and Development Overview
    • Key Therapeutic Areas
  • BioNTech AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • BioNTech AG - Pipeline Products Glance
    • BioNTech AG - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • BioNTech AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • BioNTech AG - Drug Profiles
    • NT-0001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-0002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-0003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-0004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-0005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligoneucleotide for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BioNTech AG - Pipeline Analysis
  • BioNTech AG - Pipeline Products by Route of Administration
  • BioNTech AG - Pipeline Products by Molecule Type
  • BioNTech AG - Dormant Projects
  • BioNTech AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BioNTech AG, Key Information
  • BioNTech AG, Key Facts
  • BioNTech AG - Pipeline by Indication, 2015
  • BioNTech AG - Pipeline by Stage of Development, 2015
  • BioNTech AG - Monotherapy Products in Pipeline, 2015
  • BioNTech AG - Partnered Products in Pipeline, 2015
  • BioNTech AG - Partnered Products/ Combination Treatment Modalities, 2015
  • BioNTech AG - Phase I, 2015
  • BioNTech AG - Preclinical, 2015
  • BioNTech AG - Pipeline by Route of Administration, 2015
  • BioNTech AG - Pipeline by Molecule Type, 2015
  • BioNTech AG - Dormant Developmental Projects,2015
  • BioNTech AG, Subsidiaries

List of Figures

  • BioNTech AG - Pipeline by Top 10 Indication, 2015
  • BioNTech AG - Pipeline by Stage of Development, 2015
  • BioNTech AG - Monotherapy Products in Pipeline, 2015
  • BioNTech AG - Partnered Products in Pipeline, 2015
  • BioNTech AG - Pipeline by Top 10 Route of Administration, 2015
  • BioNTech AG - Pipeline by Top 10 Molecule Type, 2015
Back to Top